Opendata, web and dolomites

Vacc-iNTS SIGNED

Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Vacc-iNTS project word cloud

Explore the words cloud of the Vacc-iNTS project. It provides you a very rough idea of what is the project "Vacc-iNTS" about.

collaborative    resource    network    antibodies    bacteria    immunogenicity    limited    settings    trials    shigella    typhimurium    fatality    academia    outer    tackling    salmonellosis    transcriptomics    countries    poor    lots    data    vacc    suited    vaccine    safety    generate    rapid    immunogenic    ints    bactericidal    20    experts    antibiotic    african    resistance    infectious    released    strains    roadblocks    profit    invasive    bridges    gmma    sub    serum    manufacturing    africa    membrane    antigens    sonnei    genetically    serotypes    olds    disease    adults    biology    epidemiological    healthy    263    advocate    blebs    modified    advocacy    typhoidal    scalable    generalized    industry    difficult    modules    gap    levels    diagnosis    advancing    proof    antibody    saharan    lt    strengthen    deployment    clinical    deaths    rate    sero    cellular    proposes    endemic    animals    integration    enteritidis    stage    accelerate    preclinical    ssa    followed    trial    drive    gmp   

Project "Vacc-iNTS" data sheet

The following table provides information about the project.

Coordinator
SCLAVO VACCINES ASSOCIATION 

Organization address
address: PIAZZA LA LIZZA 7
city: SIENA
postcode: 53100
website: www.sclavo.org/home

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 0 €
 EC max contribution 6˙871˙188 € (0%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Two-Stage-RTD
 Funding Scheme RIA-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2024-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SCLAVO VACCINES ASSOCIATION IT (SIENA) coordinator 1˙152˙311.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 2˙227˙288.00
3    GSK VACCINES INSTITUTE FOR GLOBAL HEALTH SRL IT (SIENA) participant 1˙576˙515.00
4    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 545˙942.00
5    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 432˙034.00
6    UNIVERSITA DEGLI STUDI DI SIENA IT (SIENA) participant 341˙017.00
7    KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY KUMASI GH (KUMASI) participant 194˙226.00
8    UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO BF (OUAGADOUGOU 03) participant 192˙980.00
9    KENYA MEDICAL RESEARCH INSTITUTE KE (Nairobi) participant 107˙575.00
10    UNIVERSITY OF OTAGO NZ (DUNEDIN) participant 50˙000.00
11    PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE BE (ANTWERPEN) participant 31˙296.00
12    MMGH CONSULTING GMBH CH (ZURICH) participant 20˙000.00

Map

 Project objective

Invasive non-typhoidal Salmonellosis (iNTS) is an important emerging Neglected Infectious Disease in resource-poor settings of sub-Saharan Africa (sSA). No vaccine is currently available. Estimated 263,000 iNTS deaths per year in <5 year olds, a 20% case fatality rate, difficult diagnosis and increasing antibiotic resistance strongly advocate for rapid development of an effective vaccine. Vacc-iNTS bridges the gap between preclinical and early clinical development of a novel vaccine against iNTS, based on GMMA (Generalized Modules for Membrane Antigens) from the most common African iNTS serotypes (Typhimurium and Enteritidis). The highly cost-effective GMMA-technology, developed by partner 2, is based on outer membrane blebs released by genetically modified bacteria. Clinical proof-of-concept for the GMMA-technology was achieved with a Shigella sonnei vaccine in European and African adults. In animals, iNTS-GMMA were highly immunogenic and induced antibodies with bactericidal activity against African iNTS strains. Simple, robust and scalable manufacturing processes for iNTS-GMMA, suited for sSA, have been developed. Vacc-iNTS proposes GMP manufacturing of clinical lots followed by a two-stage Phase 1 trial in healthy European and African adults to investigate safety and immunogenicity of the iNTS-GMMA vaccine. Analysis include serum antibody levels and functionality, cellular responses, transcriptomics and data integration through a systems biology approach. Sero-epidemiological analysis will be conducted to provide essential data for future Phase 2 and 3 trials. Vacc-iNTS will also strengthen a collaborative network of iNTS experts from academia, industry and non-profit including partners from disease-endemic countries of sSA. The network will generate data to accelerate further vaccine development, enhance awareness, drive advocacy and vaccine deployment in limited-resources disease-endemic countries, tackling major roadblocks in advancing a vaccine against iNTS.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VACC-INTS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VACC-INTS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More